Sökning: WFRF:(Elmer E.) > Cyclosporine-A enha...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 02813naa a2200409 4500 | |
001 | oai:lup.lub.lu.se:cc8583a0-437e-4095-8a9c-24bf97f3861f | |
003 | SwePub | |
008 | 160401s2000 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/11168212 URI |
024 | 7 | a https://doi.org/10.1016/S0304-3940(99)00962-32 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Borlongan, C V4 aut |
245 | 1 0 | a Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats |
264 | 1 | c 2000 |
520 | a Cyclosporine-A (CsA) is the primary anti-rejection drug used for organ and neural transplantation therapy. In addition to its immunosuppressive action, CsA has been recently shown to exert neuroprotective and neurotrophic effects in the central nervous system when able to cross the blood-brain barrier. Postulated mechanisms for these CsA-induced beneficial effects include the drug's powerful inhibition of the calcium-dependent phosphatase calcineurin (CN) and blockade of the assembly of the mitochondrial permeability transition pore. We report here, for the first time, that adult Wistar rats treated with CsA (10 mg/kg per day, i.p. for 9 days) displayed significantly reduced septal CN expression in combination with enhanced levels of septal choline acetyltransferase (ChAT) immunoreactivity as compared to controls. The observed enhancement of septal ChAT immunoreactivity suggests potential therapeutic utility of CsA for brain disorders characterized by alterations of the cholinergic system. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
653 | a Alzheimer’s disease | |
653 | a Septum | |
653 | a Cholinergic system | |
653 | a Immunosuppression | |
653 | a Neurotrophic effects | |
653 | a Calcineurin | |
653 | a Mitochondrial permeability transition pore | |
700 | 1 | a Stahl, C E4 aut |
700 | 1 | a Keep, M F4 aut |
700 | 1 | a Elmer, Eskilu Lund University,Lunds universitet,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)expb-eel |
700 | 1 | a Watanabe, S4 aut |
710 | 2 | a Sektion IVb Institutionen för kliniska vetenskaper, Lund4 org |
773 | 0 | t Neuroscience Lettersg 279:2, s. 73-76q 279:2<73-76x 0304-3940 |
856 | 4 | u http://dx.doi.org/10.1016/S0304-3940(99)00962-3y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/1116821 |
856 | 4 8 | u https://doi.org/10.1016/S0304-3940(99)00962-3 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.